IFNG 139 a.a. Human
Greater than 90.0% as determined by analysis by SDS-PAGE.
Description
IFNG 139 a.a. is purified by proprietary chromatographic techniques.
Product Specs
The IFNG 139 a.a. protein solution is provided at a concentration of 1 mg/ml. The formulation includes phosphate-buffered saline (PBS) at a pH of 7.4 and 10% glycerol.
The purity of the product exceeds 90%, as determined by SDS-PAGE analysis.
The biological activity of IFNG was evaluated using a cytotoxicity assay with WiDr cells. The ED50, representing the effective dose for 50% cytotoxicity, was found to be less than or equal to 0.5 ng/ml.
MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFRG.
Product Science Overview
Recombinant human IFN-γ is typically produced in Escherichia coli (E. coli) and supplied in a lyophilized form to ensure stability . The molecular weight of this recombinant protein is approximately 17 kDa . The protein is highly purified, with purity levels exceeding 95% as determined by SDS-PAGE .
IFN-γ is known for its antiviral, immunoregulatory, and anti-tumor properties. It activates macrophages and natural killer (NK) cells, enhancing their cytotoxic activity . Additionally, IFN-γ promotes the production of other cytokines and increases the expression of major histocompatibility complex (MHC) molecules, thereby boosting antigen presentation and adaptive immune responses .
Recombinant IFN-γ is used in various research applications, including:
- Virus protection assays: It is used to determine the bioactivity of IFN-γ by assessing its ability to protect cells from viral infections .
- Immunological studies: Researchers use IFN-γ to study its effects on immune cells and its role in diseases such as autoimmune disorders and cancer .
- Therapeutic potential: IFN-γ has been explored as a therapeutic agent for conditions like chronic granulomatous disease and severe osteopetrosis .
Recombinant human IFN-γ is stable in its lyophilized form at -20°C. Once reconstituted, it should be stored at 4°C for short-term use or at -20°C to -80°C for long-term storage to prevent loss of potency . It is recommended to add a carrier protein, such as human serum albumin (HSA) or bovine serum albumin (BSA), for long-term storage .
